Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Immunol. 2012 Mar 22;12(4):269-81. doi: 10.1038/nri3191.

Adoptive immunotherapy for cancer: harnessing the T cell response.

Author information

1
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. restifon@mail.nih.gov

Abstract

Immunotherapy based on the adoptive transfer of naturally occurring or gene-engineered T cells can mediate tumour regression in patients with metastatic cancer. Here, we discuss progress in the use of adoptively transferred T cells, focusing on how they can mediate tumour cell eradication. Recent advances include more accurate targeting of antigens expressed by tumours and the associated vasculature, and the successful use of gene engineering to re-target T cells before their transfer into the patient. We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication.

PMID:
22437939
DOI:
10.1038/nri3191
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center